Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gem-Doce versus BCG for high-risk non-muscle invasive bladder cancer
ISRCTN92816346Phase 3Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Aug 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, docetaxel and bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), transitional cell carcinoma of the bladder (TCC) and Bladder cancer in situ (CIS) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: High-grade recurrence-free survival. Started Aug 2026; status: recruiting.
02
Drugs
gemcitabinedocetaxelbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on ISRCTN92816346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN92816346.